Physician profile
Clinton H Sharp
NPI 1508855198
$12,263.88
in general payments reported to CMS, 2019-2025
51 companies · $1,943 in 2025
The $1,943 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $1,684 · 2021: $1,731 · 2022: $1,411 · 2023: $1,714 · 2024: $2,105 · 2025: $1,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,750 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,750.33 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,975.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,716.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,455.12 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $879.54 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $649.49 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $551.72 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Pfizer INC. | $421.39 | 2019-2025 | |
| Amgen INC. | $347.24 | 2019-2024 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $318.02 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $303.07 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.23 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Exact Sciences Corporation | $221.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $219.11 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $206.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $201.13 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.